COMMUNIQUÉS West-GlobeNewswire

NEOVACS obtient une nouvelle « Investigational New Drug (IND) » de la FDA dans la dermatomyosite aux Etats-Unis

19/07/2017 - 07:30

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE Néovacs annonce avoir obtenu une nouvelle « Investigational New Drug ( IND ) » de la FDA pour élargir son programme de développement clinique avec l' [...]

Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis

19/07/2017 - 07:30

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis This is the second clinical trial approved by [...]

ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne

18/07/2017 - 20:18

ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne ELB021 est un anticorps [...]

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

18/07/2017 - 20:18

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU ELB021 is a proprietary first-in-class monoclonal antibody targeting [...]

PHARMAGEST INTERACTIVE : acquisition majeure sur le marché de l'informatique hospitalière

18/07/2017 - 19:00

Villers-lès-Nancy, le 18 Juillet 2017 - 19h00 (CET) COMMUNIQUE DE PRESSE SYSTEME D'INFORMATION DE SANTE A L'HOPITAL ACQUISITION MAJEURE MALTA INFORMATIQUE, filiale du Groupe PHARMAGEST ( Euronext Paris #FR 0012882389 - [...]

SPINEWAY : Croissance confirmée sur le 1er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%)

18/07/2017 - 18:30

Communiqué de presse Ecully, le 18 juillet 2017 Croissance confirmée sur le 1 er semestre 2017 Chiffre d'affaires de 6M€ (+ 146%) En Milliers d'euros 2016 2017* 1 er trimestre 1 109 3 110 2 ème trimestre 1 330 2 901 CA [...]

SPINEWAY : Confirmed growth Revenue for the first half of 2017: €6M (+146%)

18/07/2017 - 18:30

Press release Ecully, 18 July 2017 Confirmed growth Revenue for the first half of 2017: €6M (+146%) In thousands of euros 2016 2017* 1 st quarter 1 109 3 110 2 nd quarter 1 330 2 901 HY 1 revenue 2 439 6 010 * Figures [...]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

18/07/2017 - 18:00

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...

18/07/2017 - 18:00

Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

NICOX : Nombre de droits de vote au 17 juillet 2017

18/07/2017 - 17:40

Nicox SA Société anonyme au capital de 25 669 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 17 juillet 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]

NICOX : Number of voting rights as of July 17, 2017

18/07/2017 - 17:40

Number Nicox SA Société anonyme with a registered capital of € 25,669,338 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On July 17, 2017, MONTHLY PUBLICATION OF [...]

Summit Therapeutics plc : Result of AGM

18/07/2017 - 16:41

Summit Therapeutics plc ('Summit' or 'the Company') RESULT OF ANNUAL GENERAL MEETING Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing [...]

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

18/07/2017 - 15:00

FIT Biotech Oy Company release July 18, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]

Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody

18/07/2017 - 13:00

Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and commercialization of a novel, potentially [...]

Shire plc : Notice of Results

18/07/2017 - 13:00

Shire to announce second quarter 2017 results Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017. Results press release will be [...]

Allergy Therapeutics: Trading Update

18/07/2017 - 13:00

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update 15% constant currency revenue growth Double-digit compound annual revenue growth over the past 18 years 18 July 2017 Allergy Therapeutics [...]

Midatech Pharma Plc: Trading Update and Notice of Results

18/07/2017 - 13:00

18 July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Trading Update and Notice of Results Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing [...]

uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing

18/07/2017 - 13:00

Patent Covers Overlapping Rep78/52 Nucleotide Sequences for Robust, Large-Scale Production of AAV Constructs LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE [...]

Enzymatica recruits Chief Commercial Officer

18/07/2017 - 08:30

Press release Lund, 18 July 2017 Enzymatica recruits Chief Commercial Officer Enzymatica has recruited Claus Egstrand as its Chief Commercial Officer. Claus Egstrand's primary responsibility will be to develop [...]